英国乳腺癌Ki-67免疫组化染色与判读建议
该指南由英国病理学界制定,针对乳腺癌Ki-67免疫组化染色与判读提出标准化建议。指南强调分析前变量控制、推荐简化校准整体评估法及经验证的AI算法,并讨论Ki-67在新辅助及辅助治疗决策中的价值,旨在提高判读可重复性并推动临床安全应用。
要点
- 推荐使用简化校准整体评估法替代 exhaustive 视觉定量,以缩短判读时间并降低变异。
- 有条件时应采用经验证的图像分析/人工智能算法进行Ki-67判读。
- 固定 cut-off 值存在局限,可考虑分层分类或连续建模。
核心结论
- Ki-67是乳腺癌尤其是HR阳性/HER2阴性 disease 的重要预后与预测标志物,其临床价值需通过严格标准化、经验证判读方法和病理-肿瘤科密切沟通来实现。
研究设计与样本
- 本文件为英国病理学界制定的指南/综述,总结Ki-67生物学基础、技术要求和分析前/分析变量影响,评估现有与新兴判读方法并给出判读建议。
主要发现
- Ki-67判读的观察者间和实验室间变异限制了其临床实施。
- 简化校准整体评估法可保持准确性并大幅缩短判读时间,避免估计方法的变异。
- 经验证的图像分析/AI算法已显示可提高可重复性、缩短周转时间,且预后性能优于手动判读。
- Ki-67可预测新辅助内分泌和化疗反应,可整合入PEPI等预后模型,并有助于筛选辅助CDK4/6抑制剂治疗患者。
关键数值与推荐
- 推荐采用简化校准整体评估法作为 exhaustive 视觉定量的替代方案。
- 有条件时推荐使用经验证的图像分析/人工智能算法进行Ki-67判读。
- 固定 cut-off 值存在局限性,应讨论分层分类和连续建模的潜在优势。
临床怎么用
- 病理科应规范Ki-67免疫组化分析前与分析环节,采用简化校准整体评估法或经验证AI算法进行判读。
- 判读结果应与肿瘤科沟通,结合临床背景用于预后评估和治疗决策。
局限性
- 原文未报告具体研究样本量、阈值、P值等数值。
- 原文未系统列出各判读方法的具体准确性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ki-67 is a well-established marker of tumour proliferation and an important prognostic and predictive biomarker in breast cancer, particularly in hormone receptor-positive (HR-positive), HER2-negative disease. Despite its biological relevance, clinical implementation has been limited by the reported interobserver and interlaboratory variability. Recent therapeutic advances have created an increased need for accurate and reproducible Ki-67 assessment in clinical practice. This review summarizes the biological basis for the use of Ki-67 as a marker of proliferation, technical requirements for reliable immunohistochemistry and the influence of pre-analytical and analytical variables on staining performance. We evaluate established and emerging scoring approaches and provide scoring recommendations for practising pathologists. A simplified calibrated global assessment method is presented as an alternative to exhaustive visual quantification that preserves its accuracy while substantially reducing scoring time and avoiding the variability of estimated methods. Image analysis/artificial intelligence (AI) using validated algorithms is recommended where available. We also review the role of Ki-67 in predicting response to neoadjuvant endocrine and chemotherapy, its integration into prognostic models such as the PEPI score, and its utility in selecting patients for adjuvant CDK4/6 inhibition. The limitations of fixed cut-off values are discussed, together with the potential advantages of tiered classification and continuous modelling. Finally, we outline the growing role of digital pathology and AI, which have demonstrated improved reproducibility, reduced turnaround time, and prognostic performance superior to manual scoring. Ki-67 is a clinically meaningful biomarker, the value of which can only be fully realized through rigorous standardization, validated scoring approaches and close communication between pathologists and oncologists. This guidance provides a practical framework for high-quality Ki-67 assessment and supports its safe and effective integration into contemporary breast cancer management.
引用
- Shaaban AM, Dodson A, Rakha E, et al. UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer. Histopathology. 2026. PMID: 42470171. doi:10.1111/his.70235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。